European Ultibro nod gives Novartis boost in COPD race
This article was originally published in Scrip
Executive Summary
The expected entry of Ultibro Breezhaler into the COPD market following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on 25 July will considerably advance Novartis's position within the market.